Nexgel Inc (NXGL) - Net Assets
Based on the latest financial reports, Nexgel Inc (NXGL) has net assets worth $5.58 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($11.62 Million) and total liabilities ($6.04 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Nexgel Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $5.58 Million |
| % of Total Assets | 47.99% |
| Annual Growth Rate | 28.98% |
| 5-Year Change | 8463.38% |
| 10-Year Change | N/A |
| Growth Volatility | 5604.46 |
Nexgel Inc - Net Assets Trend (2016–2024)
This chart illustrates how Nexgel Inc's net assets have evolved over time, based on quarterly financial data. Also explore NXGL asset base for the complete picture of this company's asset base.
Annual Net Assets for Nexgel Inc (2016–2024)
The table below shows the annual net assets of Nexgel Inc from 2016 to 2024. For live valuation and market cap data, see NXGL market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $6.08 Million | +17.69% |
| 2023-12-31 | $5.17 Million | -32.36% |
| 2022-12-31 | $7.64 Million | -36.81% |
| 2021-12-31 | $12.09 Million | +16921.13% |
| 2020-12-31 | $71.00K | -81.32% |
| 2019-12-31 | $380.00K | +35.23% |
| 2018-12-31 | $281.00K | -55.04% |
| 2017-12-31 | $625.00K | -21.28% |
| 2016-12-31 | $794.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Nexgel Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1799600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $8.00K | 0.14% |
| Other Components | $23.74 Million | 412.56% |
| Total Equity | $5.75 Million | 100.00% |
Nexgel Inc Competitors by Market Cap
The table below lists competitors of Nexgel Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PayPoint plc
LSE:PAY
|
$4.73 Million |
|
Qualigen Therapeutics Inc
NASDAQ:QLGN
|
$4.74 Million |
|
SILVER HAMMER MINING CORP
F:7BW0
|
$4.74 Million |
|
Basin Energy Ltd
AU:BSN
|
$4.74 Million |
|
CN Asia Corporation Bhd
KLSE:7986
|
$4.73 Million |
|
Bank Permata Tbk
JK:BNLI
|
$4.73 Million |
|
Nutritional Growth Solutions Ltd
AU:NGS
|
$4.71 Million |
|
Global Engine Group Holding Limited Ordinary Shares
NASDAQ:GLE
|
$4.71 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nexgel Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,697,000 to 5,755,000, a change of 1,058,000 (22.5%).
- Net loss of 3,281,000 reduced equity.
- New share issuances of 3,772,000 increased equity.
- Other factors increased equity by 567,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.28 Million | -57.01% |
| Share Issuances | $3.77 Million | +65.54% |
| Other Changes | $567.00K | +9.85% |
| Total Change | $- | 22.53% |
Book Value vs Market Value Analysis
This analysis compares Nexgel Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.66x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 4.07x to 0.66x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $0.14 | $0.58 | x |
| 2017-12-31 | $0.11 | $0.58 | x |
| 2018-12-31 | $0.05 | $0.58 | x |
| 2019-12-31 | $0.07 | $0.58 | x |
| 2020-12-31 | $0.01 | $0.58 | x |
| 2021-12-31 | $2.17 | $0.58 | x |
| 2022-12-31 | $1.37 | $0.58 | x |
| 2023-12-31 | $0.83 | $0.58 | x |
| 2024-12-31 | $0.88 | $0.58 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nexgel Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -57.01%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -37.76%
- • Asset Turnover: 0.79x
- • Equity Multiplier: 1.91x
- Recent ROE (-57.01%) is above the historical average (-551.65%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -223.68% | -82.53% | 1.71x | 1.59x | $-1.86 Million |
| 2017 | -152.48% | -47.84% | 2.23x | 1.43x | $-1.02 Million |
| 2018 | -671.89% | -85.31% | 2.99x | 2.63x | $-1.92 Million |
| 2019 | -506.05% | -268.20% | 0.38x | 4.97x | $-1.96 Million |
| 2020 | -3188.73% | -335.91% | 0.30x | 31.79x | $-2.27 Million |
| 2021 | -35.66% | -277.89% | 0.09x | 1.41x | $-5.52 Million |
| 2022 | -62.14% | -231.74% | 0.20x | 1.36x | $-5.51 Million |
| 2023 | -67.21% | -77.21% | 0.41x | 2.12x | $-3.63 Million |
| 2024 | -57.01% | -37.76% | 0.79x | 1.91x | $-3.86 Million |
Industry Comparison
This section compares Nexgel Inc's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $1,863,507,886
- Average return on equity (ROE) among peers: -17.76%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nexgel Inc (NXGL) | $5.58 Million | -223.68% | 1.08x | $4.73 Million |
| Akoya Biosciences Inc (AKYA) | $121.35 Million | -35.38% | 0.57x | $64.44 Million |
| Align Technology Inc (ALGN) | $1.35 Billion | 32.89% | 0.86x | $12.66 Billion |
| AngioDynamics Inc (ANGO) | $517.03 Million | -1.36% | 0.37x | $444.32 Million |
| AptarGroup Inc (ATR) | $2.71 Billion | 14.48% | 0.94x | $7.66 Billion |
| AtriCure Inc (ATRC) | $16.74 Million | -22.66% | 1.01x | $1.44 Billion |
| Avinger Inc (AVGR) | $-73.64 Million | 0.00% | 0.00x | $1.52 Million |
| Anteris Technologies Global Corp. Common Stock (AVR) | $10.52 Million | -163.15% | 1.04x | $156.14 Million |
| Avantor Inc (AVTR) | $5.57 Billion | -9.53% | 1.12x | $5.43 Billion |
| Azenta Inc (AZTA) | $553.69 Million | -12.55% | 0.24x | $1.04 Billion |
| Baxter International Inc (BAX) | $7.87 Billion | 19.65% | 1.00x | $8.85 Billion |
About Nexgel Inc
NEXGEL, Inc. manufactures and sells high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It operates through two segments: Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications; and beauty and cosmetic solut… Read more